Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire October 28, 2021

Bristol Myers Squibb Reports Third Quarter Financial Results for 2021

Business Wire October 27, 2021

Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)

Business Wire October 25, 2021

TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors

GlobeNewswire October 25, 2021

BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

Business Wire October 22, 2021

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …

Business Wire October 21, 2021

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

Business Wire October 20, 2021

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Business Wire October 15, 2021

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Business Wire October 13, 2021

BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

Business Wire October 7, 2021

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

Business Wire October 7, 2021

Bristol Myers Squibb to Hold Investor Event on November 16

Business Wire October 1, 2021

European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma

Business Wire October 1, 2021

European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Business Wire October 1, 2021

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

Business Wire September 30, 2021

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Business Wire September 27, 2021

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

Business Wire September 20, 2021

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5

Business Wire September 17, 2021

Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Business Wire September 16, 2021

According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types

Business Wire September 13, 2021